May I welcome this step that’s been taken? The principle is established in terms of this drug. It’s the practicalities that are important to the sufferers of this cancer for which this drug has been designed. So, two simple questions: when, practically speaking, will this drug be available in Wales, and how long will patients have to wait to receive a prescription to access this drug?

And one further question on another drug that Breast Cancer Now has raised concerns about. Whilst welcoming the agreement on Kadcyla, I will quote from Delyth Morgan, the chief executive of Breast Cancer Now:

daw’r newyddion hwn ar adeg pan fo posibilrwydd gwirioneddol y gallai’r defnydd o Perjeta— esgusodwch fi os nad wyf wedi’i ynganu’n gywir— y driniaeth gyntaf ar gyfer y grŵp hwn o gleifion, ddod i ben cyn bo hir yn y GIG, gyda phenderfyniad ar fin digwydd. Mae manteision Perjeta yn eithriadol, yn cynnig bron i 16 mis ychwanegol o fywyd i fenywod â chanser y fron na ellir ei wella, ac mae’n hanfodol ein bod yn dod o hyd i ffordd o achub y cyffur hwn, ar gost sy’n fforddiadwy i’r GIG a’r trethdalwr.

So, whilst we welcome the decision on Kadcyla, can you give us an update on this other drug?